French company Abivax and the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba announced an agreement here today to partner in the development and commercialization of vaccines, among them, one against the Hepatitis B virus.
The CIGB, Cuba's leading biotechnology institution, has more than 50
research-development projects, while Abivax, based in Paris, is a
product of the merger of the Wittycell, Splicos and Zophis firms. Their
objective is to fight infectious diseases and cancer.